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Abstract
Background and Aims Ischemia following acute myo-
cardial infarction (AMI) increases the level of pro-fibrotic
and inflammatory cytokines, including transforming
growth factor (TGF)-b and tumor necrosis factor (TNF)-a.
N-acetylcysteine (NAC) has therapeutic benefits in the
management of patients with AMI. To the best of our
knowledge, this is the first study that has evaluated the
effect of NAC on TNF-a and TGF-b levels in patients with
AMI.
Methods Following confirmation of AMI, 88 patients
were randomly administered NAC 600 mg (Fluimucil,
Zambon, Ticino, Switzerland) or placebo orally twice daily
for 3 days. For quantification of TGF-b and TNF-a serum
levels after 24 and 72 h of NAC or placebo administration,
peripheral venous blood (10 mL) samples were collected at
these time points.
Results Comparisons between levels of TGF-b and TNF-
a after 24 and 72 h within the NAC or placebo groups
revealed that there was not any significant difference
except for TGF-b levels in the placebo group, which
increased significantly over time (p = 0.042). Significant
relationships existed between patients’ ejection fraction
(p = 0.005) and TGF-b levels.
Conclusions Receiving NAC could prevent TGF-b levels
from increasing after 72 h as compared with not receiving
NAC. As TGF-b had strong correlations with the ejection
fraction, its antagonism seems to be important in the pre-
vention of remodeling.
1 Introduction
Acute myocardial infarction (AMI) triggers an ischemic
state in the myocardium, after which a process of remod-
eling is initiated by gradual myocardial ventricular dilation,
hypertrophy, and distortion of left ventricular (LV)
geometry [1]. The remodeling process, which can be cat-
egorized into the two phases of early (B72 h) and late
([72 h) [2], is considered to be a determinant of mortality
and morbidity in patients after AMI [3]. Several mecha-
nisms contribute to the remodeling process, includingRegistration no.: IRCT201102283449N5 at http://www.irct.ir.
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myocardial cell death, fibrotic changes in cardiomyocytes
following collagen synthesis, and inflammation due to
increased expression of pro-inflammatory cytokines [4–6].
Ischemia following AMI provoked an increase in the
level of main pro-fibrotic cytokine, transforming growth
factor (TGF)-b, which induces fibrotic depositions in the
cardiomyocytes [7]. TGF-b plays a significant role in the
pathogenesis of the remodeling process, as its inhibition in
the proliferative phase of remodeling can prevent the LV
from hypertrophy and decrease the extent of fibrosis in the
non-infarcted segments of the myocardium and improve
LV geometry [8, 9].
On the other hand, AMI is associated with acute up-
regulation of pro-inflammatory cytokines, with tumor
necrosis factor (TNF)-a being the most important [10].
TNF-a stimulated the remodeling process and provoked
myocardial dysfunction after AMI [11–13]. Moreover,
TNF-a can increase the expression of angiotensin receptor
in the cardiac fibroblasts of animal models, which
increased the activity of angiotensin and therefore induced
fibrotic changes [14].
N-acetylcysteine (NAC), previously recognized as an
acetaminophen antidote, has been used in different clinical
situations because of its antioxidant, free radicals scaven-
ger, and glutathione-replenishing properties [15]. NAC is
hypothesized to have numerous therapeutic benefits in the
management of cardiovascular diseases, including post-
AMI cardiac remodeling [16–18]. In animal models of
ischemia and reperfusion, NAC decreased infarct size [19,
20]. In combination with thrombolytics, NAC reduced
oxidative stress, induced a trend toward more rapid reper-
fusion, and enhanced preservation of LV function [21, 22].
Although glutathione is considered to have a major role
in preserving body homeostasis and protecting cells against
toxic agents, it is not transported well into cells due to its
large molecular size. Moreover, L-cysteine, the amino acid
involved in the intracellular synthesis of glutathione, is
toxic to humans. NAC can easily be deacetylated in cells to
provide L-cysteine and therefore increase the intracellular
glutathione concentration. Glutathione is a necessary factor
for the activation of T lymphocytes and polymorphonu-
clear leukocytes in addition to cytokine production [23]. As
nuclear factor (NF)-jB has a role in the inducible tran-
scription of TNF-a and oxidative stress can induce its
nuclear translocation, antioxidants including NAC can act
as potent inhibitors of NF-jB activation [24, 25]. This may
be the explanation behind how NAC might prevent the
production of TNF-a. With respect to TGF-b, NAC can
change this cytokine to its biologically inactive form and
inhibit its binding to the receptor [26]. On the other hand,
fibronectin, a glycoprotein involved in tissue remodeling,
can be released in response to a variety of cytokines
including TGF-b as its strongest stimulator. Therefore, by
inhibiting the TGF-b-induced fibronectin production, NAC
can be effective in blocking tissue remodeling [27].
To the best of our knowledge, this is the first study
evaluating the effect of NAC on TNF-a and TGF-b levels
in human subjects with AMI to investigate whether NAC
might be beneficial in reducing remodeling.
2 Methods
This randomized double-blind clinical trial (registration
no.: IRCT201102283449N5 at http://www.irct.ir) was
conducted at the Tehran Heart Centre, one of the referral
teaching hospitals for cardiovascular disorders in Tehran,
Iran from August 2010 to August 2011.
The sample size of the study (44 patients in each group)
was calculated based on the change in the serum TNF-a
concentration following NAC administration [11]. The
power of the study was considered to be 95 % (a = 0.05
and b = 0.20).
After obtaining written informed consent, patients ful-
filling diagnostic criteria for ST-segment elevation myo-
cardial infarction (STEMI) were included in the study.
However, patients with pre-hospital delays of more than
12 h, previous AMI, heart failure, atrial fibrillation, or
chronic diseases, in addition to those under treatment with
anti-inflammatory agents or antioxidants, were not eligible
for the present study. The local ethical committee approved
this trial and the investigation conforms to the principles
outlined in the Declaration of Helsinki. Following confir-
mation of STEMI, patients were randomly administered
NAC effervescent tablet 600 mg (Fluimucil, Zambon,
Ticino, Switzerland) or placebo together with their stan-
dard treatment twice daily for 3 days. The pharmacother-
apy management of all patients was the same, including
aspirin, clopidogrel, captopril, metoprolol, nitrate, and
high-dose atorvastatin (80 mg).
We documented data regarding patients’ demography,
past medical and drug history, laboratory parameters,
ischemic time [defined as the time from symptom onset to
their management either by thrombolytic therapy or pri-
mary percutaneous coronary intervention (P-PCI)], type of
management (thrombolytic or P-PCI), and echocardio-
graphic and coronary angiographic findings (number of
arteries affected) if evaluated. Echocardiography was per-
formed for all patients before discharge.
For quantification of TGF-b and TNF-a serum levels 24
and 72 h after NAC or placebo administration, peripheral
venous blood (10 mL) samples were collected at these time
points. Samples were centrifuged at 3,000 rpm for 10 min,
and serums were separated and stored at -70 C. Serum
levels of TGF-b and TNF-a were measured using com-
mercial ELISA kits (Bender MedSystems, Vienna, Austria).
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2.1 Statistical Analysis
Data were analyzed using SPSS (version 16) statis-
tical software. We reported categorical variables as
frequency counts and percentages while continuous
variables were summarized as medians and ranges or
means and standard deviations. For assessing the
normal distribution of variables, the Kolmogorov–
Smirnov test was used. The associations of TGF-b and
TNF-a serum levels with patients’ characteristics were
investigated using the chi-square statistical test or
Fisher’s exact test for discrete variables and the
Mann–Whitney test for continuous variables. Spear-
man correlation coefficient was used to evaluate the
correlation between continuous variables. A general-
ized estimating equation was used to estimate the
correlation between repeated biomarker levels. Log-
transformation was performed for non-normally dis-
tributed variables where applicable. We used two
independent samples t tests to compare levels of log-
transformed TGF-b and TNF-a between NAC and
placebo groups. A paired t test was used to compare
these biomarkers’ log-transformed levels in the NAC
and placebo groups individually.
3 Results
3.1 Comparisons Between Patients
in the N-Acetylcysteine and Placebo Groups
This prospective study was conducted on 88 patients who
fulfilled the inclusion criteria of the trial. The age range of
the studied population was 40–92 years and 72 (82 %)
were males. Patients’ demographic data, including age,
sex, past medical and drug history, ischemic time as well as
the number of subjects receiving P-PCI, did not have a
statistically significant difference in the NAC versus pla-
cebo groups (Table 1). Furthermore, the comparison of
biomarker levels measured after 24 (TGF-b-24 h, TNF-a-
24 h) and 72 (TGF-b-72 h, TNF-a-72 h) hours did not
show any statistically significant difference between the
NAC and placebo groups (Table 2). Comparisons between
levels of TGF-b and TNF-a after 24 and 72 h within the
NAC or placebo groups revealed that there was not any
significant difference except for TGF-b levels in the pla-
cebo group, which increased significantly with time passed
(p = 0.042) [Fig. 1]. Parallel comparisons were made
using the log-transformed levels of these biomarkers with
similar results.
Table 1 Comparisons of baseline characteristics between patients in the placebo and N-acetylcysteine groups
Baseline characteristics Total Groups p value
NAC Placebo
No. of patients 88 50 (57) 38 (43)
Median age, years (range) 61 (40–92) 61 (42–92) 61 (40–86) 0.374
Male sex, no. (%) 72 (82) 41 (82) 31 (82) 0.960
Median ischemic time, h (range) 3.5 (0.6–12) 3.38 (0.6–12) 4.15 (0.5–12) 0.481
Management, no. (%) 0.154
Streptokinase 53 (60) 27 (54) 26 (68)
Primary PCI 28 (32) 20 (40) 8 (21) 0.34
EF (Mean ± SD) 42.7 ± 8.1 43.4 ± 7.8 41.9 ± 8.4
Risk factor, no. (%) 88 (100) 50 (100) 38 (100)
Elderly 75 (85) 43 (86) 32 (84) 0.815
Smoker 36 (41) 21 (42) 15 (40) 0.811
Diabetes mellitus 24 (27) 16 (32) 8 (21) 0.253
Hypertension 42 (48) 25 (50) 17 (45) 0.624
Family history 19 (22) 10 (20) 9 (24) 0.677
Hyperlipidemia 34 (39) 20 (40) 14 (37) 0.763
Drug history, no. (%) 61 (69) 38 (76) 23 (61) 0.119
Cardiovascular 44 (50) 27 (54) 17 (45) 0.389
Oral anti-glycemic agents 20 (23) 13 (26) 7 (18) 0.401
Anti-hyperlipidemic 17 (19) 8 (16) 9 (24) 0.366
EF ejection fraction, NAC N-acetylcysteine, PCI percutaneous coronary intervention
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3.2 Associations of Biomarker Levels with Patient
Characteristics
We did not find any significant relationship between levels
of TGF-b-24 h, TNF-a-24 h, TGF-b-72 h, or TNF-a-72 h
and patients’ demographic data, including age and sex.
Hypertension or hyperlipidemia did not have any associa-
tions with biomarkers’ levels. However, significant rela-
tionships existed between past medical history of diabetes
mellitus and TGF-b-72 h (p = 0.033). Moreover, drug
history of statins (HMG-CoA reductase inhibitors) had a
significant association with TGF-b-72 h (p = 0.009).
Being a smoker had a relationship with the level of TNF-a-
24 h (p = 0.049). There was not any association between
type of reperfusion management and biomarker levels,
while coronary angiographic findings showed a statistically
significant relationship with the TGF-b-72 h level
(p = 0.014). The level of TGF-b-72 h had a statistically
significant difference between patients with two-vessel
disease and those with left main coronary artery (LMCA)
disease (p = 0.001). Moreover, significant differences
existed between patients with triple-vessel disease and
those with LMCA disease (p = 0.021) as the latter had
higher levels of TGF-b-72 h. In evaluating associations of
echocardiographic findings and biomarker levels, signifi-
cant relationships existed between ejection fraction and
TGF-b-72 h (p = 0.005) as well as between intraventric-
ular septum abnormality and TNF-a-24 h (p = 0.038).
3.3 Correlations Between Biomarker Levels
and Patient Characteristics
We found significant correlations between the level of
TNF-a-24 h and TGF-b-72 h (r = 0.231, p = 0.03). Sig-
nificant correlation existed between the level of TNF-a-
72 h and glycosylated hemoglobin (HbA1c) serum level
(r = 0.655, p = 0.029). The level of TGF-b-24 h had
significant correlations with ischemic time (r = -0.233,
p = 0.037) as well as cardiac troponin T levels of patients
within 6 h of admission (r = 0.218, p = 0.042), white
blood cell (WBC) count (r = 0.358, p = 0.001) and ALT
serum levels (r = 0.377, p = 0.048). Finally, significant
correlations existed between TGF-b-72 h levels and matrix
metalloproteinase (MMP)-9 measured after 72 h
(r = 0.330, p = 0.003) in addition to patients’ ejection
fraction (r = -0.311, p = 0.009).
4 Discussion
Several physiologic pathways including inflammation and
fibrosis may involve in the pathogenesis of post-myocardial
infarction (MI) structural changes called remodeling. As
TNF-a and TGF-b are known to be the major biomarkers
that contribute to each of these mentioned mechanisms and
NAC is proposed to have beneficial effects in acute
Table 2 Comparisons of biomarker levels between patients in the placebo and N-acetylcysteine groups
Biomarker (Mean ± SD) Total (N = 88) Placebo (N = 38) NAC (N = 50) p value
TNF-a-24 h 164.6 ± 65 176.4 ± 95.5 155.6 ± 20.4 0.137
TNF-a-72 h 160.6 ± 40 164.7 ± 54.1 157.5 ± 24.7 0.405
TGF-b-24 h 11,595 ± 6,327.6 11,166.4 ± 4,426.5 11,893.4 ± 7,402 0.621
TGF-b-72 h 11,983 ± 6,935.4 12,953 ± 5,180.5 11,233 ± 8,013.4 0.255
CK-MB-24 h 39.4 ± 33.3 40.9 ± 40.5 38.2 ± 26.8 0.703
CK-MB-72 h 5.32 ± 5.1 5.9 ± 6.6 4.9 ± 3.5 0.38
hs-TnT-24 h 3,115.3 ± 2,451.9 3,656.9 ± 2,648.5 2,703.6 ± 2,230.9 0.071
hs-TnT-72 h 2,285.5 ± 1,834.1 2,672.6 ± 2,160.9 1,991.4 ± 1,497.4 0.084
NAC N-acetylcysteine, TGF-b-x h transforming growth factor-b measured after x h, TNF-a-x h tumor necrosis factor-a measured after x h, CK-
MB-x h creatine kinase-MB measured after x h, hs-TnT-x h highly sensitive troponin T measured after x h
Fig. 1 The difference between transforming growth factor-b levels in
placebo and N-acetylcysteine groups over time. NAC N-acetylcyste-
ine, TGF transforming growth factor
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cardiology, in this study we evaluated the impact of NAC
on these biomarkers. TNF-a tends to peak within 24 h
following MI, and decreased toward baseline 3 days after
MI [28]. Although the TNF-a level trend was in favor of
those who received NAC, the difference was not significant
between groups.
While we could not find any significant effect on the
TNF-a level, NAC could prevent TGF-b from increasing.
In patients who received placebo the level of TGF-b
increased significantly after 72 h; however, this significant
elevation did not take place in patients in the NAC group.
Antagonism of TGF-b can lead to two opposite effects
depending on the time. Early TGF-b inhibition, within the
first 24 h after AMI, can increase levels of pro-inflamma-
tory cytokines and infiltration of neutrophils, and conse-
quently intensify the expression of MMPs which may result
in aggravation of LV dysfunction and increase the rate of
mortality [8]. Conversely, TGF-b antagonism after this
time can have beneficial effects by reducing the extent of
fibrotic and hypertrophic changes in the myocardium [9,
29, 30]. In the present study, we found that NAC did not
have any significant effect on the level of TGF-b at 24 h,
the time at which its inhibition can have a detrimental
outcome. However, NAC administration could prevent
TGF-b from increasing at 72 h as compared with patients
receiving placebo, the time at which the proliferative phase
of remodeling will start, and therefore its suppression could
have favorable therapeutic effects. Higher serum concen-
trations of TGF-b had strong positive correlations with LV
systolic function and patients’ ejection fraction in the
present study, which showed that a relationship existed
between TGF-b and cardiac remodeling. This finding puts
more emphasis on the necessity of TGF-b inhibition to
prevent cardiac remodeling and its untoward consequences.
As TGF-b was shown to promote extracellular matrix
synthesis and collagen crosslink took place after MI, it
could have an important role in the signaling pathway of
LV remodeling [31]. An increased TGF-b level after MI
was associated with the development of heart failure sec-
ondary to cardiac remodeling [31].
In the present study, a significant association was found
between serum concentrations of TGF-b and the presence
of diabetes. This finding is in line with a previous study,
which showed a relationship between elevated serum
concentrations of TGF-b and diabetes after considering
demographic, anthropometric, metabolic, and lifestyle
factors [32]. This could be explained by the mechanism of
insulin resistance as inflammation can be an important
factor in its development and thus the incidence of diabetes
[33].
Another association was between a history of statin use
and the level of TGF-b. TGF-b is one of the most important
mediators of cardiomyocyte fibrosis and hypertrophic
growth through the action of Smad proteins as an essential
component of the intracellular signaling pathway [34].
Statins can suppress the up-regulation of TGF-b induced by
angiotensin and the resultant cardiac remodeling and sys-
tolic dysfunction [35, 36]. This suppression can be attrib-
uted to the inhibition of superoxide production favored by
angiotensin [36]. Thus, the low level of TGF-b in patients
receiving statins as observed in the present study is a rea-
sonable finding.
The other finding of this study was the relationship
between the coronary angiography finding, in particular
stenosis of the LMCA, and TGF-b levels. Although acute
STEMI following LMCA stenosis is not prevalent
(0.8–5.4 %), as reported in previous studies, its mortality
rate is very high despite emergent P-PCI [37–40]. The
association of TGF-b levels with severity of coronary
artery disease (CAD) has not been consistent among pre-
vious studies. A positive relationship was seen between the
severity of CAD and TGF-b levels in the Wang et al. [41]
study, as was seen in our study. In contrast, Grainger et al.
[42] reported lower serum concentrations of TGF-b in
patients with severe CAD. Despite having positive ath-
erosclerosis plaque stabilization effects [43], TGF-b can
lead to accumulation of extracellular matrix by decreasing
the production of collagenase and promotion of athero-
sclerosis through increasing the collagen synthesis [44].
Ischemic time and cardiac troponin C levels were other
factors that had correlations with the level of TGF-b. This
could show the importance of acceleration in the reperfu-
sion management of patients with STEMI in order to
reduce the extent of remodeling. Furthermore, the corre-
lation of cardiac troponin with TGF-b levels revealed that
the extension of myocardial necrosis had a positive rela-
tionship with the degree of cardiac remodeling.
Strong positive correlations existed between WBC
counts and TGF-b levels. Due to the inflammatory state in
patients with STEMI, an increase in the number of WBCs
occurs [45]. The association of TGF-b with inflammatory
status is further elucidated with the link that existed
between TGF-b and TNF-a in this study. In previous
studies, associations of WBCs with ejection fraction as a
marker of systolic function and LV remodeling have been
reported [46]. As TGF-b is a biomarker of remodeling, the
positive correlation between its level and WBCs seems
rational. Furthermore, in a study by Walshe et al. [47],
inhibition of TGF-b led to a reduction in WBC adhesion to
endothelial cells and an increase in the WBC count, which
could be another potential explanation for this correlation.
With respect to TNF-a we observed higher levels of this
cytokine in patients who smoke than in non-smokers,
which is in line with a previous study on patients with
chronic obstructive pulmonary disease [48]. In contrast,
some other studies did not find a significant difference in
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the level of TNF-a in smokers versus non-smokers [49,
50]. Higher levels of TNF-a in patients with AMI who
smoke in the present study can develop the hypothesis that
smoking can be the stimulus of enhanced systemic
inflammation and potentially higher extension of
remodeling.
A significant positive correlation existed between the
levels of TNF-a and HbA1c. As TNF-a contributed to the
insulin resistance in patients with diabetes [51], its high
level can lead to poor glycemic control in this population
and, consequently, raised HbA1c. In concordance with
this statement, patients with concomitant rheumatoid
arthritis or Crohn’s disease and diabetes who received
anti-TNF-a therapeutic agents had significant improve-
ments in their HbA1c, which reduced from 6.5 to 5.5 %
after treatment.
Our study was not without limitations. Also, NAC is
known to reduce oxidative stress but we did not evaluate
its efficacy by measuring oxidative products. Moreover,
NAC was administered orally in this study. As enrolled
patients were suffering from STEMI and therefore
hypoperfusion, this may lead to a decrease in the possible
effects of NAC. As another limitation of this study, we
did not follow up our patients in order to assess the long-
term effects of NAC, in particular on echocardiography
parameters. Furthermore, we did not use magnetic reso-
nance imaging for the evaluation of remodeling in our
patients, which may reduce the precision of interpretation
of our findings.
5 Conclusion
This is the first study to evaluate the possible effects of
NAC on TGF-b and TNF-a levels in patients admitted
with STEMI. Administration of NAC could prevent TGF-
b levels from increasing after 72 h as compared with
patients who received placebo. As TGF-b had a strong
correlation with ejection fraction as a marker of LV
systolic function its late antagonism seems to be impor-
tant. Elucidating the role of NAC in the prevention of
cardiac remodeling post-AMI merits further larger clini-
cal trials.
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